scholarly journals Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia

Blood ◽  
2017 ◽  
Vol 129 (15) ◽  
pp. 2148-2160 ◽  
Author(s):  
Yuichiro Nakata ◽  
Takeshi Ueda ◽  
Akiko Nagamachi ◽  
Norimasa Yamasaki ◽  
Ken-ichiro Ikeda ◽  
...  

Key Points Acquired expression of CblQ367P induces sustained proliferation of myelomonocytes, multilineage dysplasia, and splenomegaly resembling CMML. Combined inhibition of PI3K and JAK2 efficiently suppressed the growth of CblQ367P-induced CMML cells.

Blood ◽  
2013 ◽  
Vol 121 (25) ◽  
pp. 5068-5077 ◽  
Author(s):  
Eric Padron ◽  
Jeffrey S. Painter ◽  
Sateesh Kunigal ◽  
Adam W. Mailloux ◽  
Kathy McGraw ◽  
...  

Key Points GM-CSF–dependent STAT5 hypersensitivity is detected in 90% of CMML samples and is enhanced by signaling mutations. Treatment with a GM-CSF–neutralizing antibody and JAK2 inhibitors reveals therapeutic potential.


2017 ◽  
Vol 1 (14) ◽  
pp. 972-979 ◽  
Author(s):  
Yanyan Zhang ◽  
Liang He ◽  
Dorothée Selimoglu-Buet ◽  
Chloe Jego ◽  
Margot Morabito ◽  
...  

Key Points Transgenic mice expressing 3 human cytokines enable expansion of CMML cells with limited stem cell engraftment. The mutational profile of CMML cells that expand in mice mirrors that of patient monocytes.


Blood ◽  
2013 ◽  
Vol 122 (16) ◽  
pp. 2807-2811 ◽  
Author(s):  
Koichi Takahashi ◽  
Naveen Pemmaraju ◽  
Paolo Strati ◽  
Graciela Nogueras-Gonzalez ◽  
Jing Ning ◽  
...  

Key Points t-CMML is associated with higher-risk cytogenetics and manifests poor prognosis. t-CMML should be recognized as one of the therapy-related myeloid neoplasms.


Blood ◽  
2015 ◽  
Vol 125 (23) ◽  
pp. 3618-3626 ◽  
Author(s):  
Dorothée Selimoglu-Buet ◽  
Orianne Wagner-Ballon ◽  
Véronique Saada ◽  
Valérie Bardet ◽  
Raphaël Itzykson ◽  
...  

Key Points An increase in the classical monocyte subset to >94% of total monocytes discriminates CMML from other monocytoses with high specificity. This characteristic increase in classical monocytes disappears in CMML patients who respond to hypomethylating agents.


2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S95-S95
Author(s):  
A Kwon ◽  
I Ibrahim ◽  
T Le ◽  
J Jaso ◽  
O Weinberg ◽  
...  

Abstract Introduction/Objective Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by sustained monocytosis, ranging from cytopenia with a dysplastic subtype to leukocytosis with a proliferative subtype, with a typical mutational profile involving TET2, ASXL1, and SRSF2. Mutation in colony-stimulating factor 3 receptor gene (CSF3R) is commonly associated with chronic neutrophilic leukemia (CNL) but exceedingly rare in CMML, particularly CSF3R T618I (~10 cases described, ~30 cases of CSF3R non-T618I mutations). We report a case of CSF3R T618I mutated CMML and compare the clinicopathologic features to reported CMML cases with and without CSF3R T618I mutations. Methods/Case Report A 27-year-old woman presented for evaluation of leukocytosis, sustained monocytosis, and anemia. Peripheral blood (PB) revealed leukocytosis (white cell count 35x109/L), left-shifted and dysplastic neutrophils (myelocytes and metamyelocytes, 5%), absolute and relative monocytosis (7x109/L, 29%), anemia (Hgb 4.3 g/dL), and thrombocytopenia. Bone marrow aspirate and core biopsy demonstrated a hypercellular marrow with increased myeloblasts (~3%, immunophenotypically aberrant by flow cytometry), increased myelomonocytic cells, and multilineage dysplasia, including ring sideroblasts and hypolobated megakaryocytes. Cytogenetic and molecular studies revealed a normal karyotype and mutations in CSF3R T618I, ASXL1, SETBP1, BCORL1, KRAS, and PTPN11. Despite the presence of a CSF3R T618I mutation, CMML was diagnosed given marked monocytosis, left- shifted neutrophils in PB, multilineage dysplasia, and immunophenotypically aberrant myeloblasts. Results (if a Case Study enter NA) NA Conclusion Our case demonstrates clinicopathological features similar to those of reported CSF3R T618I mutated CMML, i.e., a proliferative subtype and less likely to have co-occurring mutations in TET2 or SRSF2, which is distinct from CSF3R non-T618I mutated CMML; the latter often has a dysplastic subtype and mutational profile of frequent TET2 and SRSF2 mutations, similar to CSF3R unmutated CMML. While additional cases with this unusual mutation need to be studied to arrive at a more definitive conclusion, the CSF3R T618I mutation seems to define a unique proliferative subtype CMML with a distinct mutational profile.


2018 ◽  
Vol 2 (15) ◽  
pp. 1807-1816 ◽  
Author(s):  
Sanam Loghavi ◽  
Dawen Sui ◽  
Peng Wei ◽  
Guillermo Garcia-Manero ◽  
Sherry Pierce ◽  
...  

Key Points Validation of the WHO 2017 CMML categories supports distinguishing MP-CMML from MDS–CMML. The prognostic value of the new 3-tiered blast-based CMML stratification scheme is limited.


Blood ◽  
2013 ◽  
Vol 121 (15) ◽  
pp. 3005-3015 ◽  
Author(s):  
Esperanza Such ◽  
Ulrich Germing ◽  
Luca Malcovati ◽  
José Cervera ◽  
Andrea Kuendgen ◽  
...  

Key Points CMML is a heterogeneous disorder with a highly variable prognosis that clearly requires a specific and widely accepted prognostic scoring system. CPSS is a powerful prognostic score that defines 4 risk groups for survival and AML evolution, developed and validated in the largest CMML series to date.


2019 ◽  
Vol 3 (7) ◽  
pp. 952-955 ◽  
Author(s):  
Ami B. Patel ◽  
Erin M. Pettijohn ◽  
Sameem M. Abedin ◽  
Evan Raps ◽  
Michael W. Deininger

Key Points CMML patients comprise an elderly and frail patient population with comorbidities that often require surgical intervention. Postsurgical leukemoid reaction, a life-threatening complication in CMML patients, may be driven by molecular mechanisms.


Sign in / Sign up

Export Citation Format

Share Document